Genentech's Avastin sales miss expectations in fourth quarter
Genentech reported Monday that its fourth-quarter net income rose 6 percent to $632 million over the year-ago period. Avastin's quarterly sales climbed 23 percent to $603 million, but fell short of analysts' expectations of $616 million.
Rituxan's fourth-quarter sales rose 6 percent to $596 million, while Herceptin's revenue climbed 2 percent to $327 million. Lucentis' quarterly sales were $197 million, a 9-percent decrease compared with the year-ago quarter. Commenting on the results, Robert W. Baird's Christopher Raymond, stated: "It's not much to write home about -- they were light on product revenues." The analyst noted that "Avastin was light, and it's a key number," adding that both Rituxan and Herceptin's quarterly sales were also lower than Wall Street estimates. Total revenue for the quarter was in line with analysts' forecasts at $2.97 billion, compared with $2.71 billion in the year-ago quarter.
The company also reported full-year results, stating that net income rose 31 percent to $2.8 billion on revenue of $11.7 billion. Avastin's full-year sales rose 32 percent to $2.3 billion while Rituxan recorded a 10-percent increase in revenue to $2.3 billion for 2007. Sales of Herceptin were up 4 percent to $1.3 billion for the year.
Additionally, the drugmaker specified that it decided not to continue development of its topical VEGF product, telbermin, for diabetic foot ulcers, following negative Phase II results. Looking forward, CEO Arthur Levinson stated that in 2008, the company "will continue to invest in the 20 new molecular entities in clinical development and look forward to new data from a number of potentially important line extensions, including Rituxan for multiple sclerosis and lupus and Avastin in combination with Tarceva for advanced non-small-cell lung cancer."
FDA approves Tysabri for use in Crohn's disease
The FDA granted expanded approval to Elan and Biogen’s Tysabri for the treatment of Crohn’s disease, Elan announced Monday. The company indicated that the drug should be made available for patients with the disease by the end of February.
The product is now indicated in the US for adults with moderately-to-severely active Crohn's disease with evidence of inflammation and who have had an inadequate response to conventional therapies and TNF-alpha inhibitors. The drug will have a specific risk management plan for patients with Crohn's, Elan noted.
Tysabri, which is approved to treat multiple sclerosis in the US and EU, received a negative opinion in the EU for Crohn's disease last year.
France backs cervical cancer vaccination with Gardasil
France's High Council for Public Health on Monday announced that girls 14 years of age should be vaccinated with cervical cancer vaccine Gardasil. The vaccine, which is sold in Europe by Sanofi Pasteur MSD, a joint venture between Merck & Co. and sanofi-aventis, protects against four strains of human papillomavirus.
The agency, which said the vaccine should protect against four HPV strains, also suggested that vaccination should be offered to women aged 15 to 23 years either before, or within a year, of their first sexual contact. Gardasil competes against GlaxoSmithKline's Cervarix, which protects against two strains of HPV.
Novo Nordisk discontinues development of inhaled insulin, AERx
Novo Nordisk will discontinue development of its AERx inhalable insulin product and plans to eliminate jobs as a result, the company reported Monday. The drugmaker said the move follows an analysis of future medical and commercial prospects for inhaled insulin.
Mads Krogsgaard Thomsen, Novo Nordisk's chief scientific officer, stated that Pfizer's recent move to end sales of its inhalable insulin product, Exubera, prompted Novo Nordisk's decision. Meanwhile, company spokesperson Lori Moore stated that a "significant number" of the 360 workers at the drugmaker's plant in Hayward, California will lose their jobs as a result of the decision.
Novo Nordisk said it will take a charge of 1.3 billion Danish kroner ($260 million) in the fourth quarter related to AERx.
Blog Archive
Wednesday, January 16, 2008
Pharma News Update: January 16, 2008
Fortune scolds Merck for "risky" programs
Fortune writer John Simons is taking Merck to task for two development programs he finds particularly risky. "The riskiest of Merck's current projects is taranabant," writes Simons, "a treatment that until recently was hailed as an elegant solution for attacking excess weight. Rather than working in the gut, taranabant manipulates the brain to suppress appetite. More specifically, the drug acts on the same receptors in the brain that cause marijuana-smokers to experience hunger. Taranabant, in essence, causes a patient to experience the reverse-munchies."
Psychiatric side effects could derail that program, says Fortune. The there's the cholesterol medicine, anacetripib, which bears far too close a resemblance for Simons to Pfizer's infamous torcetrapib. Towards the end of the piece there's at least one analyst willing to agree that Merck is taking big risks, but stands to gain enormous rewards. Sounds like the kind of bet the Big Pharma developers should make more often if they want to find a way to a brighter, richer future. The last thing biopharma needs now is an even more cautious approach to drug development
AstraZeneca launches head-to-head trial comparing Crestor and Lipitor
AstraZeneca on Tuesday announced the launch of a clinical trial to compare Crestor with Pfizer’s Lipitor for the treatment of atherosclerosis in patients with coronary artery disease.
The SATURN study will compare the 40-milligram dose of Crestor with the 80-milligram dose of Lipitor in about 1300 high-risk patients and is designed to measure the ability of the statins to decrease progression or induce regression of atherosclerosis, following two years of treatment.
The trial is expected to be completed in 2011, AstraZeneca noted
Forest's third-quarter profit up 21 percent on drug sales
Forest reported Tuesday that its profit in the third quarter rose 21 percent to $301.8 million over the prior-year quarter, on strong sales of Lexapro and Namenda. The drugmaker also raised its earnings forecast for its fiscal year ending March 31.
In the quarter, sales of Lexapro grew 11 percent to $603.5 million, while sales of Namenda jumped 26 percent to $218.7 million. Overall, third-quarter revenue was $998.2 million, a 12-percent increase over the same quarter in 2006, and higher than analysts' expectations of $947 million.
Regarding its pipeline, the drugmaker anticipates launching its recently approved hypertension drug, Bystolic, this month
HRT increases risk of lobular breast cancer, study
Study results suggest that combination hormone replacement therapy may raise the risk of lobular breast cancer after just three years. The findings are published in the January edition of Cancer Epidemiology, Biomarkers and Prevention.
"Previous research indicated that five or more years of combined hormone-therapy use was necessary to increase overall breast-cancer risk," noted lead researcher Christopher Li. However, Li added that "our study...suggests that a significantly shorter exposure may confer an increased risk."
In the trial, the researchers examined the histories of 1044 postmenopausal women with breast cancer and 469 postmenopausal women without the disease. The results showed that those who took combined HRT for as few as three years were about three times more likely to develop lobular breast tumours compared with those who did not take combined HRT.
Experts have indicated that the incidence of lobular cancer is increasing, and Li noted that "our research suggests that the use of postmenopausal HRT, specifically combined preparations, may be contributing to this
European regulators approve GlaxoSmithKline's Avamys
The European Commission granted marketing authorisation to GlaxoSmithKline’s allergic rhinitis drug, Avamys, the drugmaker announced Tuesday. The treatment is the first intranasal corticosteroid to show "consistently significant improvements" in both nose and eye allergy symptoms, the drugmaker noted.
In the EU, the once-daily nasal spray is indicated for use in adults, adolescents and children aged six to 11 years. The drug was approved by the FDA in April 2007 and is marketed as Veramyst in the US
Fortune writer John Simons is taking Merck to task for two development programs he finds particularly risky. "The riskiest of Merck's current projects is taranabant," writes Simons, "a treatment that until recently was hailed as an elegant solution for attacking excess weight. Rather than working in the gut, taranabant manipulates the brain to suppress appetite. More specifically, the drug acts on the same receptors in the brain that cause marijuana-smokers to experience hunger. Taranabant, in essence, causes a patient to experience the reverse-munchies."
Psychiatric side effects could derail that program, says Fortune. The there's the cholesterol medicine, anacetripib, which bears far too close a resemblance for Simons to Pfizer's infamous torcetrapib. Towards the end of the piece there's at least one analyst willing to agree that Merck is taking big risks, but stands to gain enormous rewards. Sounds like the kind of bet the Big Pharma developers should make more often if they want to find a way to a brighter, richer future. The last thing biopharma needs now is an even more cautious approach to drug development
AstraZeneca launches head-to-head trial comparing Crestor and Lipitor
AstraZeneca on Tuesday announced the launch of a clinical trial to compare Crestor with Pfizer’s Lipitor for the treatment of atherosclerosis in patients with coronary artery disease.
The SATURN study will compare the 40-milligram dose of Crestor with the 80-milligram dose of Lipitor in about 1300 high-risk patients and is designed to measure the ability of the statins to decrease progression or induce regression of atherosclerosis, following two years of treatment.
The trial is expected to be completed in 2011, AstraZeneca noted
Forest's third-quarter profit up 21 percent on drug sales
Forest reported Tuesday that its profit in the third quarter rose 21 percent to $301.8 million over the prior-year quarter, on strong sales of Lexapro and Namenda. The drugmaker also raised its earnings forecast for its fiscal year ending March 31.
In the quarter, sales of Lexapro grew 11 percent to $603.5 million, while sales of Namenda jumped 26 percent to $218.7 million. Overall, third-quarter revenue was $998.2 million, a 12-percent increase over the same quarter in 2006, and higher than analysts' expectations of $947 million.
Regarding its pipeline, the drugmaker anticipates launching its recently approved hypertension drug, Bystolic, this month
HRT increases risk of lobular breast cancer, study
Study results suggest that combination hormone replacement therapy may raise the risk of lobular breast cancer after just three years. The findings are published in the January edition of Cancer Epidemiology, Biomarkers and Prevention.
"Previous research indicated that five or more years of combined hormone-therapy use was necessary to increase overall breast-cancer risk," noted lead researcher Christopher Li. However, Li added that "our study...suggests that a significantly shorter exposure may confer an increased risk."
In the trial, the researchers examined the histories of 1044 postmenopausal women with breast cancer and 469 postmenopausal women without the disease. The results showed that those who took combined HRT for as few as three years were about three times more likely to develop lobular breast tumours compared with those who did not take combined HRT.
Experts have indicated that the incidence of lobular cancer is increasing, and Li noted that "our research suggests that the use of postmenopausal HRT, specifically combined preparations, may be contributing to this
European regulators approve GlaxoSmithKline's Avamys
The European Commission granted marketing authorisation to GlaxoSmithKline’s allergic rhinitis drug, Avamys, the drugmaker announced Tuesday. The treatment is the first intranasal corticosteroid to show "consistently significant improvements" in both nose and eye allergy symptoms, the drugmaker noted.
In the EU, the once-daily nasal spray is indicated for use in adults, adolescents and children aged six to 11 years. The drug was approved by the FDA in April 2007 and is marketed as Veramyst in the US
Tuesday, January 8, 2008
UK Government seeks 10% drugs price cut – FT report
Suggestions that the UK government is looking to push for a 10% cut in the prices of prescription medicines on the National Health Service have raised eyebrows within the pharmaceutical industry. The Financial Times has this morning reported that Alan Johnson, the UK’s health minister, told the newspaper he plans to generate substantial savings in the £11 billion annual drugs budget during talks with industry representatives concerning the Pharmaceutical Price Regulation Scheme.This 10% figure will come as a shock to drugmakers especially as they signed a five-year deal in 2004 offering price cuts of around 7% in return for increased allowances to encourage R&D of innovative products.The Department of Health surprised drugmakers in August by saying that renegotiation of the PPRS was needed, a move which came after the UK’s Office of Fair Trading published its controversial report on the PPRS, which concluded that the NHS could save up to £500 million a year. The August statement prompted a cautious response from the Association of the British Pharmaceutical Industry which said it recognised the Government’s need to gain best value for money from all aspects of NHS services, but pointed out that the system already benefits “from one of the most cost-effective medicines policies in Europe, with high levels of generics prescribed”.The ABPI told PharmaTimes World News that it is weighing up the comments of Mr Johnson and may make a statement later today.
Tysabri doing well after relaunch
Ireland’s Elan Corp and its US partner Biogen Idec have released more favourable sales and safety data on their multiple sclerosis drug Tysabri. The firms said that as of late December, more than 21,000 patients were on Tysabri (natalizumab) and to date, the safety data “continue to support a favourable benefit-risk profile”. Specifically, in the USA, approximately 12,900 patients were on the drug on a commercial basis and 2,500 physicians have prescribed the therapy. Most interestingly, Elan and Biogen added that there have been no cases of progressive multifocal leukoencephalopathy, a rare brain disease, since the re-launch of Tysabri in July 2006. The drug was pulled off the market on safety concerns in February 2005, and its reintroduction came with restrictions to monitor patients for symptoms of PML. Tysabri is key to the fortunes of both firms (but especially Elan) and a joint meeting of the US Food and Drug Administration’s Gastrointestinal Drugs Drug Safety and Risk Management Advisory Committee voted 12 to three back in August to support the treatment in Crohn’s disease. However, European regulators have looked less favourably on the Crohn’s indication and adopted a negative opinion on the marketing authorisation filing in November.
New DPP4 inhibitor on the way
Takeda Pharmaceutical Co has filed its new diabetes treatment alogliptin with US regulators in a bid to reduce its reliance on Actos and start making up ground on Merck & Co’s dipeptidyl peptidase-4 inhibitor Januvia. The Japanese drugmaker has submitted a New Drug Application to the US Food and Drug Administration for SYR-322 (alogliptin), a DPP-4 inhibitor for the once-daily treatment of type 2 diabetes. DPP-4 inhibitors are a new class of oral agents that target the incretin system and it is thought that they reduce glucose more effectively without producing the side effects of present treatments. The NDA submission was supported by six Phase III trials involving over 2,000 patients in 220 centers worldwide. The safety and efficacy of alogliptin was studied as a once-daily monotherapy adjunct to diet and exercise and as an add-on therapy to other medications including sulfonylureas, insulin metformin and thiazolidinediones,such as Takeda’s big-earning Actos (pioglitazone). In the studies, alogliptin was associated with statistically significant reductions in haemoglobin A1c, which reflects average blood glucose concentration over the previous two to three months. It was generally well-tolerated and weight neutral and there was no increase in hypoglycaemia compared to placebo. The Osaka-based firm’s president Yasuchika Hasegawa said that the NDA submission is a significant milestone for Takeda “as it has the potential to position us as one of the global leaders in diabetes treatment". He added that the company’s continued growth, “now and in the future, will be based on our ability to focus and have success in this therapeutic area”. If approved, a launch for alogliptin could take place in early 2009, and analysts believe it could bring in $2 billion a year. However it will have a lot of ground to make up on Merck’s Januvia (sitagliptin) which has already been available in the USA since October 2006, while Novartis will be hoping the FDA finally look favourably on its DPP-4 inhibitor Galvus (vildagliptin) before Takeda’s product hits the market. Moving into this new area of diabetes treatment is also important for Takeda given that Actos will be hit by patent expiries in the USA in 2011. The drug, despite receiving stronger label warnings recently, brought in around $2.86 billion in the last fiscal year, more than 25% of the firm’s total revenues. TAK-390MR also filed Separately, TAP Pharmaceutical Products, Takeda's US joint venture with Abbott Laboratories, said it has submitted an NDA to the FDA for TAK-390MR, a proton pump inhibitor to treat diseases caused by stomach acid, including reflux. "This compound and its novel delivery system is a promising next step in the management of erosive and non-erosive esophagitis," said Nancy Joseph Ridge, vice president of R&D at TAP.
Subscribe to:
Comments (Atom)